Multiple factors affect immunogenicity of DNA plasmid HIV vaccines in human clinical trials.

Plasmid DNA vaccines have been licensed for use in domesticated animals because of their excellent immunogenicity, but none have yet been licensed for use in humans. Here we report a retrospective analysis of 1218 healthy human volunteers enrolled in 10 phase I clinical trials in which DNA plasmids encoding HIV antigens were administered. Elicited T-cell immune responses were quantified by validated intracellular cytokine staining (ICS) stimulated with HIV peptide pools. HIV-specific binding and neutralizing antibody activities were also analyzed using validated assays. Results showed that, in the absence of adjuvants and boosting with alternative vaccines, DNA vaccines elicited CD8+ and CD4+ T-cell responses in an average of 13.3% (95% CI: 9.8-17.8%) and 37.7% (95% CI: 31.9-43.8%) of vaccine recipients, respectively. Three vaccinations (vs. 2) improved the proportion of subjects with antigen-specific CD8+ responses (p=0.02), as did increased DNA dosage (p=0.007). Furthermore, female gender and participants having a lower body mass index were independently associated with higher CD4+ T-cell response rate (p=0.001 and p=0.008, respectively). These vaccines elicited minimal neutralizing and binding antibody responses. These findings of the immunogenicity of HIV DNA vaccines in humans can provide guidance for future clinical trials.

[1]  P. Westfall,et al.  Multiple Tests with Discrete Distributions , 1997 .

[2]  Guido Ferrari,et al.  Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers. , 2007, Vaccine.

[3]  W. Blattner,et al.  Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. , 2011, The Journal of infectious diseases.

[4]  U. Ehlert,et al.  Higher body mass index (BMI) is associated with reduced glucocorticoid inhibition of inflammatory cytokine production following acute psychosocial stress in men , 2008, Psychoneuroendocrinology.

[5]  Donald K Carter,et al.  HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case–cohort analysis , 2008, The Lancet.

[6]  P. McKay,et al.  Enhanced Immunogenicity of an HIV-1 DNA Vaccine Delivered with Electroporation via Combined Intramuscular and Intradermal Routes , 2014, Journal of Virology.

[7]  P. van Damme,et al.  Hepatitis A/B vaccination of adults over 40 years old: comparison of three vaccine regimens and effect of influencing factors. , 2006, Vaccine.

[8]  W. Blattner,et al.  Safety and Immunogenicity of an HIV-1 Gag DNA Vaccine with or without IL-12 and/or IL-15 Plasmid Cytokine Adjuvant in Healthy, HIV-1 Uninfected Adults , 2012, PloS one.

[9]  Allan C. deCamp,et al.  HIV-DNA Priming Alters T Cell Responses to HIV-Adenovirus Vaccine Even When Responses to DNA Are Undetectable , 2011, The Journal of Immunology.

[10]  M. McElrath,et al.  Defining blood processing parameters for optimal detection of cryopreserved antigen-specific responses for HIV vaccine trials. , 2007, Journal of immunological methods.

[11]  Laurie Lamoreaux,et al.  Priming Immunization with DNA Augments Immunogenicity of Recombinant Adenoviral Vectors for Both HIV-1 Specific Antibody and T-Cell Responses , 2010, PloS one.

[12]  T. Wu,et al.  Innovative DNA vaccine to break immune tolerance against tumor self-antigen. , 2013, Human gene therapy.

[13]  D. O'Shea,et al.  Changes in human dendritic cell number and function in severe obesity may contribute to increased susceptibility to viral infection , 2013, International Journal of Obesity.

[14]  Vidya Subramanian,et al.  Obesity, inflammation, and macrophages. , 2009, Nestle Nutrition workshop series. Paediatric programme.

[15]  Peter B Gilbert,et al.  Peptide selection for human immunodeficiency virus type 1 CTL-based vaccine evaluation. , 2006, Vaccine.

[16]  A. Agresti,et al.  Approximate is Better than “Exact” for Interval Estimation of Binomial Proportions , 1998 .

[17]  D. Weiner,et al.  Vaccination of seronegative volunteers with a human immunodeficiency virus type 1 env/rev DNA vaccine induces antigen-specific proliferation and lymphocyte production of beta-chemokines. , 2000, The Journal of infectious diseases.

[18]  D. Weiner,et al.  Comparative ability of plasmid IL-12 and IL-15 to enhance cellular and humoral immune responses elicited by a SIVgag plasmid DNA vaccine and alter disease progression following SHIV(89.6P) challenge in rhesus macaques. , 2007, Vaccine.

[19]  D. Montefiori,et al.  Safety and Immunogenicity of an HIV Adenoviral Vector Boost after DNA Plasmid Vaccine Prime by Route of Administration: A Randomized Clinical Trial , 2011, PloS one.

[20]  M. Jensen,et al.  Leptin-based adjuvants: an innovative approach to improve vaccine response. , 2013, Vaccine.

[21]  N. Sardesai,et al.  Immunotherapy Against HPV16/18 Generates Potent TH1 and Cytotoxic Cellular Immune Responses , 2012, Science Translational Medicine.

[22]  Donald K Carter,et al.  Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery. , 2013, The Journal of infectious diseases.

[23]  J. Mascola,et al.  A Human T-Cell Leukemia Virus Type 1 Regulatory Element Enhances the Immunogenicity of Human Immunodeficiency Virus Type 1 DNA Vaccines in Mice and Nonhuman Primates , 2005, Journal of Virology.

[24]  S. Han,et al.  Obesity with a body mass index under 30 does not significantly impair the immune response in young adults. , 2011, Nutrition research.

[25]  R. Kennedy,et al.  Preclinical prophylactic efficacy testing of Sm-p80-based vaccine in a nonhuman primate model of Schistosoma mansoni infection and immunoglobulin G and E responses to Sm-p80 in human serum samples from an area where schistosomiasis is endemic. , 2011, The Journal of infectious diseases.

[26]  Xiping Wei,et al.  Human Immunodeficiency Virus Type 1 env Clones from Acute and Early Subtype B Infections for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies , 2005, Journal of Virology.

[27]  M. Hudgens,et al.  Obesity is associated with impaired immune response to influenza vaccination in humans , 2011, International Journal of Obesity.

[28]  Margaret A. Liu.  DNA vaccines: an historical perspective and view to the future , 2011, Immunological reviews.

[29]  W. Blattner,et al.  Timing of plasmid cytokine (IL-2/Ig) administration affects HIV-1 vaccine immunogenicity in HIV-seronegative subjects. , 2011, The Journal of infectious diseases.

[30]  K. Clément,et al.  CD14dimCD16+ and CD14+CD16+ Monocytes in Obesity and During Weight Loss: Relationships With Fat Mass and Subclinical Atherosclerosis , 2011, Arteriosclerosis, thrombosis, and vascular biology.

[31]  James A. Williams.  Improving DNA vaccine performance through vector design. , 2014, Current gene therapy.

[32]  Zoe Moodie,et al.  Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccination. , 2007, Journal of immunological methods.

[33]  Vicki C. Ashley,et al.  Initial B-Cell Responses to Transmitted Human Immunodeficiency Virus Type 1: Virion-Binding Immunoglobulin M (IgM) and IgG Antibodies Followed by Plasma Anti-gp41 Antibodies with Ineffective Control of Initial Viremia , 2008, Journal of Virology.

[34]  Devan Mehrotra,et al.  Detection of HIV Vaccine-Induced Cell-Mediated Immunity in HIV-Seronegative Clinical Trial Participants Using an Optimized and Validated Enzyme-Linked Immunospot Assay , 2007, Journal of acquired immune deficiency syndromes.

[35]  J. Mascola,et al.  Heterologous Envelope Immunogens Contribute to AIDS Vaccine Protection in Rhesus Monkeys , 2004, Journal of Virology.

[36]  D. Weiner,et al.  Synthetic DNA Vaccines: Improved Vaccine Potency by Electroporation and Co-Delivered Genetic Adjuvants , 2013, Front. Immunol..

[37]  Allan C. deCamp,et al.  A novel HIV T helper epitope-based vaccine elicits cytokine-secreting HIV-specific CD4+ T cells in a Phase I clinical trial in HIV-uninfected adults. , 2009, Vaccine.

[38]  Mary S. Wu,et al.  Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine. , 2000, Vaccine.

[39]  S. Hoffman,et al.  Induction of CD4+ T cell-dependent CD8+ type 1 responses in humans by a malaria DNA vaccine , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[40]  S. Sugano,et al.  Screening of novel malaria DNA vaccine candidates using full-length cDNA library. , 2013, Experimental parasitology.

[41]  Zoe Moodie,et al.  Statistical positivity criteria for the analysis of ELISpot assay data in HIV-1 vaccine trials. , 2006, Journal of immunological methods.

[42]  W. Blattner,et al.  A Phase IIA Randomized Clinical Trial of a Multiclade HIV-1 DNA Prime Followed by a Multiclade rAd5 HIV-1 Vaccine Boost in Healthy Adults (HVTN204) , 2011, PloS one.